Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon

Affiliations

¹ University Hospital Grosshadern, Munich, and German Cancer Consortium and German Cancer Research Centre, Heidelberg, Germany.
² ClinAssess, Leverkusen, Germany.
³ University Hospital Grosshadern, Munich, and German Cancer Consortium and German Cancer Research Centre, Heidelberg, Germany volker.heinemann@med.uni-muenchen.de.

Comment

Dominik Paul Modest et al. J Clin Oncol. 2016.

. 2016 May 1;34(13):1565-6.

doi: 10.1200/JCO.2015.66.3799. Epub 2016 Mar 7.

¹ University Hospital Grosshadern, Munich, and German Cancer Consortium and German Cancer Research Centre, Heidelberg, Germany.
² ClinAssess, Leverkusen, Germany.
³ University Hospital Grosshadern, Munich, and German Cancer Consortium and German Cancer Research Centre, Heidelberg, Germany volker.heinemann@med.uni-muenchen.de.

No abstract available

Comment on

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Modest DP, et al. J Clin Oncol. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261259 Clinical Trial.
Best Sequence Therapy in RAS Wild-Type Metastatic Colorectal Cancer: Waiting for Randomized Crossover Clinical Trials.
Nasti G, Ottaiano A. Nasti G, et al. J Clin Oncol. 2016 May 1;34(13):1563-4. doi: 10.1200/JCO.2015.65.9086. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951319 No abstract available.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial.
Avallone A, Budillon A. Avallone A, et al. J Clin Oncol. 2016 May 1;34(13):1564. doi: 10.1200/JCO.2015.66.1512. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951321 No abstract available.